Scientists are reporting discovery of a protein in the blood of lung cancer patients that could be used in a test for the disease — difficult to diagnose in its earliest and most treatable stages — and to develop drugs that stop lung cancer fr…
Tag Archives | lung cancer patients
Study links vitamin D to lung cancer survival
ANN ARBOR, Mich. — Recent research suggests vitamin D may be able to stop or prevent cancer. Now, a new study finds an enzyme that plays a role in metabolizing vitamin D can predict lung cancer survival.
The study, from researchers at the U…
Spontaneous smoking cessation may be an early symptom of lung cancer, research suggests
Many longtime smokers quit spontaneously with little effort shortly before their lung cancer is diagnosed, leading some researchers to speculate that sudden cessation may be a symptom of lung cancer.
Most patients who quit did so before noticing a…
Fish oil fights weight loss due to chemotherapy
A new analysis has found that supplementing the diet with fish oil may prevent muscle and weight loss that commonly occurs in cancer patients who undergo chemotherapy. Published early online in Cancer, a peer-reviewed journal of the American Cancer …
Erlotinib effective and with fewer side-effects after first-line treatment
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient’s cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial…
Quick, easy test identifies aggressive type of lung cancer in never-smokers
An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found.
Dr P…
Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer
Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.
Dr Rafael Rosell and colleagues reported their findings at the European M…
Anti-estrogen medication reduces risk of dying from lung cancer
A new study has found that tamoxifen, an anti-estrogen breast cancer medication, may reduce an individual’s risk of death from lung cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study supports …
New combo lung cancer therapy improves survival over single-line treatment
AURORA, Colo. (Dec. 14, 2010) — A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results from…
Personalized molecular therapy shows promising results for people with advanced lung cancer
A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. T…
Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival
— Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 20…
Fewer guessing games for lung cancer patients
Reston, Va. — A study published in the December issue of The Journal of Nuclear Medicine identified positron emission tomography/computed tomography (PET/CT) scans as a potentially useful tool for predicting local recurrence in lung cancer patien…
People with specific kind of lung cancer respond to new targeted treatment
AURORA, Colo. (Oct. 28, 2010) – A study in the New England Journal of Medicine shows more than half of patients with a specific kind of lung cancer are responding positively to a treatment that targets the gene that drives their cancer.
T…
Proton therapy safe, effective for early-stage lung cancer patients
Proton beam therapy is safe and effective and may be superior to other conventional treatments for Stage I inoperable non-small cell lung cancer (NSCLC) patients, according to a study in the October issue of the International Journal of Radiation On…
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial…
Gene mutation predicts outcome for lung cancer patients
Patients with the earliest form of the most common type of lung cancer are more than twice as likely to die of the disease within four years if they have a mutation in a well known cancer-causing gene, scientists have found. The study in the July 2 issue of the Journal of the National Cancer Institute also shows that lung cancer patients who both smoke and consume alcohol frequently are more likely to have the mutation.
Vaccine technique shows potential against common form of lung cancer
In a demonstration of vaccine therapy’s potential for treating lung cancer, scientists report that a prototype vaccine boosted the natural immune response to tumors in a small group of patients with advanced non-small cell lung cancer (NSCLC). Moreover, the vaccine was found to be non-toxic and well-tolerated. Published in the Feb. 15 issue of the Journal of Clinical Oncology, findings from the Phase I clinical trial will provide an impetus for further efforts to develop a vaccine against NSCLC, a difficult-to-treat condition that accounts for roughly 80 percent of all lung cancer cases.